Drug Profile


Alternative Names: BAY W 6228; Baycol; Certa; Cervasta; Cholstat; Lipobay; Liposterol; Micro®; Rivastatin; Selta; Staltor; Stativa™; Vaslip; Zenas Micro

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Developer Bayer; Chiesi; Ferrer; Fournier Pharma; Fournier Pharma Inc; GlaxoSmithKline; Laboratorios Vita
  • Class Antihyperlipidaemics; Pyridines
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemias; Low HDL cholesterol

Most Recent Events

  • 24 Apr 2003 Groupe Fournier is now called Fournier Pharma
  • 23 Aug 2001 Withdrawn for Hypercholesterolaemia in Japan (PO)
  • 09 Aug 2001 Bayer has withdrawn cerivastatin worldwide except in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top